ENDRA Life Sciences to Present at the 11th Annual LD Micro Main Event on December 5, 2018
Management to Live Webcast Company Presentation
ANN ARBOR, MI / ACCESSWIRE / December 3, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NDRA), a developer of enhanced ultrasound technologies, has been invited to present at the 11th Annual LD Micro Main Event being held on December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
ENDRA CEO Francois Michelon and CFO David Wells are scheduled to present on Wednesday, December 5, 2018 at 3:30 pm Pacific time in Track 3 and will hold one-on-one meetings throughout the conference.
The company will also be webcasting its formal presentation for those who cannot attend the LD Micro Conference. To access the live webcast, please go to: http://wsw.com/webcast/ldmicro15/ndra/ or the company's investor relations website here. The webcast will be archived for 90 days following the live presentation.
For additional information or to schedule a one-on-one meeting with ENDRA management, please contact your LD Micro representative. You may also email your request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.
About the 11th Annual LD Micro Main Event
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) which covers stocks in North America with market capitalizations between $50 million to $300 million. It is a non-registered investment advisor. For more details, please click here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. (''ENDRA'') (NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
SOURCE: ENDRA Life Sciences Inc.
